Jackson Liang, Principal Scientist at Genentech, shared on LinkedIn:
“A little late in sharing this since I was recently out on parental leave, but better late than never!
I am excited to share our latest work investigating resistance to giredestrant in post-1L ER+ metastatic breast cancer patients, now published in Nature Communications.
Next-generation SERDs demonstrated clinical activity in recent clinical trials of post-1L ER+ metastatic breast cancer.
However, responses to these drugs were highly heterogeneous: across trials and independent of ESR1 status, 30–50% of patients progressed by their first follow-up scan.
To interrogate the basis of this heterogeneous response, our team analyzed giredestrant-treated patients. Critically, we find that giredestrant-resistant disease exhibits loss of luminal lineage identity and by extension, ERα dependence.
We further model this form of resistance in vitro, in hopes of identifying therapeutic options for advanced, ER-independent disease.”
Title: Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER+ HER2− locally-advanced or metastatic breast cancer
Authors: Jackson Liang, Christy Ong, Kareem Heslop, Jane Guan, Vasumathi Kameswaran, Bence Daniel, Minyi Shi, Yuxin Liang, Jennifer M. Giltnane, Junko Aimi, Ching-Wei Chang, Mary R. Gates, Jennifer Eng-Wong, Pablo Perez-Moreno, Komal L. Jhaveri, Nicholas C. Turner, Elgene Lim, Ciara Metcalfe, Heather M. Moore
Other articles about breast cancer on OncoDaily.